Research programme: nucleic acid therapeutics - Promosome/Unknown company
Latest Information Update: 28 Oct 2020
Price :
$50 *
At a glance
- Originator Promosome; Unknown
- Developer Promosome
- Class DNA vaccines; Gene therapies; Nucleic acids, nucleotides, and nucleosides; RNA vaccines
- Mechanism of Action RNA interference; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 07 Sep 2016 mRNA engineering technologies developed at the Scripps Research Institute licensed to Promosome, world-wide, before September 2016 (Promosome website, September 2016)
- 07 Sep 2016 Promosome and an Unknwon company enter into a collaboration for the development of nucleic acid therapeutics based on Promosome's mRNA engineering tools